IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue…
Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.02%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.51%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.32%. September E-mini S&P futures (ESU26) rose +0.02%, and Se…
Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.02%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.51%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.32%. September E-mini S&P futures (ESU26) rose +0.02%, and Se…
Top Midday Decliners
MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Stocks Fall from Early Highs as Chipmakers Retreat
The S&P 500 Index ($SPX) (SPY) today is up +0.11%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.54%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%. September E-mini S&P futures (ESU26) are up +0.11%, and September E-mini…
Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more
Check out some of the companies making the biggest moves midday: ASML — The maker of semiconductor manufacturing equipment slid 8%. China began mass production of domestically made deep ultraviolet chipmaking tools, The Information reporte…
Stocks Rally as Middle East Tensions Ease
The S&P 500 Index ($SPX) (SPY) today is up +0.65%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.08%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.56%. September E-mini S&P futures (ESU26) are up +0.65%, and September E-mini N…
Stocks Fall from Early Highs as Chipmakers Retreat
The S&P 500 Index ($SPX) (SPY) today is up +0.11%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.54%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%. September E-mini S&P futures (ESU26) are up +0.11%, and September E-mini…
Stocks Rally as Middle East Tensions Ease
The S&P 500 Index ($SPX) (SPY) today is up +0.65%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.08%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.56%. September E-mini S&P futures (ESU26) are up +0.65%, and September E-mini N…
MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%
(RTTNews) - MapLight Therapeutics (MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg tw…
Markets News, July 27, 2026: Nasdaq Slips as Chip Stocks Drop, Dow Rises; Oil Prices Plunge on Pause in US-Iran Hostilities
Four of the Magnificent Seven mega-cap tech companies are set to report results this week. Credit: Spencer Platt / Getty Images Major indexes logged mixed results to start the busiest week of the corporate earnings season, as chip stocks w…
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the best biotech stocks on this list. TheFly reported on June 24 that Raymond James initiated cover…
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology. Regulatory m…
MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents
(RTTNews) - MapLight Therapeutics, Inc. (MPLT) announced topline results from its Phase 2 IRIS study evaluating ML-004 in patients with autism spectrum disorder (ASD). The trial did not meet its primary endpoint measuring improvement in so…
Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…
MapLight Therapeutics Says IRIS Phase 2 Trial Did Not Meet Its Primary Endpoint; Stock Down 10.5%
(RTTNews) - Biopharmaceutical company MapLight Therapeutics, Inc. (MPLT) announced Monday that the IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with autism spectrum disorder (ASD). IRIS (…
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Key Points Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. After the sale, Nan Fung's remaining stake of 350,745 shares was valued at approximately $9.3 million -- r…
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the quar…
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
What happened According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11 million, based on the quarte…
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
Key Points FCPM III Services B.V. initiated a new position in Damora Therapeutics, adding 2,441,000 shares last quarter; the estimated trade size was $65.63 million (quarterly average pricing). The quarter-end value of the new Damora Thera…
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securitie…
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
Setia Vishwas, Chief Financial Officer of MapLight Therapeutics(NASDAQ:MPLT), reported the direct sale of 36,371 shares of Common Stock over multiple open-market transactions from May 4 to May 6, 2026, for a total consideration of approxim…
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
MapLight Therapeutics(NASDAQ:MPLT) Chief Administrative and Accounting Officer Jonathan Gillis disclosed the direct sale of 69,835 shares of common stock in multiple open-market transactions on April 27 and April 28, 2026, according to an…
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
Anatol Kreitzer, the chief discovery officer of MapLight Therapeutics(NASDAQ:MPLT), reported the direct sale of 3,316 shares of Common Stock for a total transaction value of approximately $88,000, according to the SEC Form 4 filing. Transa…
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
Key Points An MPLT executive reported selling 3,316 shares directly on April 15, 2026, for a transaction value of approximately $88,000 at an average price of $26.61 per share. No indirect or derivative shares were involved in the transact…
TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the must-buy small cap stocks to buy. On April 7, TD Cowen analyst Joseph Thome initiated coverage on MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating. The analyst cited the co…
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham sa…
MapLight Reports FY25 Results, Expects Multiple Phase 2 Readouts In 2026
(RTTNews) - MapLight Therapeutics, Inc. (MPLT), a clinical-stage biopharmaceutical company developing treatments for debilitating central nervous system disorders, reported fourth-quarter and full-year 2025 financial results and highlighte…
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies,…
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an inves…
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes
* MapLight Therapeutics (NASDAQ:MPLT [https://seekingalpha.com/symbol/MPLT]) has been added to the Russell 2000 Index and the broader Russell 3000 Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 202…
MapLight To Report Schizophrenia Trial Results In 2H 2026
(RTTNews) - MapLight Therapeutics Inc. (MPLT), on Thursday, reported its third-quarter 2025 financial results and highlighted recent progress across its pipeline. The company's lead drug candidate is ML-007C-MA, a muscarinic M1/M4 agonist…
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More
JHVEPhoto / iStock Editorial via Getty Images In the past week or so, beneficial owners took advantage of MapLight Therapeutics Inc.’s (NASDAQ: MPLT) initial public offering. Meanwhile, the executive board chair of Kinder Morgan Inc. (NYSE…